Week 1-4: Initial Tolerance and Minimal Weight Loss

Week 1: Injection given (0.25 mg). Minimal appetite change; slight nausea possible in 20-30% of users. Weight: unchanged (0-2 lb loss expected). Week 2: Mild appetite suppression beginning; nausea may peak in some users. Weight: 0-2 lb loss. Week 3: Appetite suppression noticeable; some users report food aversions; nausea improving in most. Weight: 0-3 lb loss. Week 4: Dose escalates to 0.5 mg. Appetite suppression moderate; nausea often resolves. Weight: 2-5 lb loss total. Key point: weight loss in this phase is minimal despite appetite changes because steady-state drug levels take 4 weeks to establish. Users expecting dramatic early loss are often disappointed; patience is critical.

Week 4-8: Steady-State Reached and Acceleration Begins

Week 5-6: Steady-state drug levels achieved; appetite suppression maximal at current dose. Weight loss accelerates: 0.5-1 lb/week. Week 7-8: Sustained weight loss continuing; users noticing changes in clothing fit, appetite control remarkable compared to baseline. Total weight loss by week 8: 5-10 lbs (range 3-15 lbs depending on starting weight and baseline metabolism). Important distinction: some weight loss early is water/glycogen depletion (accounting for 30-40% of loss in first weeks); fat loss becomes predominant after week 4. Users noticing rapid early loss should expect the rate to slow after week 4-6 as this water loss concludes.

Week 8-16: Optimal Weight Loss Phase

Dose escalates to 1.0 mg at week 8-12. Appetite suppression maximal; weight loss accelerates to 1-2 lb/week. By week 12: 8-20 lbs lost (average 12 lbs). By week 16: 12-28 lbs lost (average 18 lbs). This phase has the best weight loss rate; metabolic factors align optimally (maximal appetite suppression, increased satiety, stable energy deficit). Users typically feel the medication working during this period and have the most confidence in the treatment.

Week 16-24: Continued Progress and Dose Optimization

Dose may escalate to 1.7 mg or 2.4 mg during this phase (depending on protocol and tolerability). By week 20: 15-35 lbs lost (average 25 lbs). By week 24: 18-40 lbs lost (average 30 lbs). Weight loss rate begins to slow slightly (0.75-1.5 lb/week) as weight decreases and baseline metabolism adjusts. Total percentage body weight loss by week 24: 7-15% for most users. The visible changes become obvious—photos from week 0 vs. week 24 show substantial differences.

Week 24-52: Plateau Approaching and Long-Term Sustainability

Weeks 24-36: Weight loss continues but at slower rate (0.5-1 lb/week). By week 32: 25-50 lbs lost (average 40 lbs). Weeks 36-52: Weight loss rate further slows (0.25-0.5 lb/week); approach to new metabolic equilibrium. By week 52: 28-55 lbs lost (average 45 lbs); 10-20% total body weight reduction. This extended timeline reflects the reality that the body adapts to weight loss through metabolic changes (increased hunger hormones, decreased satiety hormones, reduced energy expenditure) that partially offset the appetite-suppressing effect of semaglutide. Weight loss doesn't stop, but the rate decreases as a natural biological response.

Week 52-68: Final Plateau and Equilibrium

Beyond week 52, weight loss typically plateaus at a new equilibrium weight. Most users reach maximum weight loss (15-22% body weight reduction) by 52 weeks. By week 68 (end of STEP trials): average weight loss 17-22 lbs. Some individuals continue modest loss (0.1-0.25 lb/week) through 18-24 months, but acceleration ceases. The plateau reflects achievement of a new metabolic steady-state where appetite suppression from semaglutide equals the dietary and activity patterns the user can sustain. Further weight loss beyond this point typically requires additional interventions (increased exercise, further dietary restriction) rather than semaglutide dose escalation.

Factors Affecting Speed of Weight Loss

Starting body weight: heavier individuals (BMI >40) lose faster (1.5-2.5 lb/week initially) while lighter individuals (BMI 27-30) lose slower (0.5-1 lb/week). Age: younger individuals typically lose faster. Metabolism: baseline metabolic rate, thyroid function, and insulin sensitivity influence rate. Diet quality: very low-carb or low-calorie diets enhance semaglutide effect; high-calorie diets blunt effect. Exercise: regular physical activity (150+ min/week) enhances weight loss 15-25% over sedentary users. Sleep: inadequate sleep (<6 hours) impairs weight loss 10-20%. Stress: high cortisol from stress impairs weight loss. Prior weight loss attempts: individuals with history of rapid weight cycling may lose more slowly (metabolic adaptation). Individual variation is substantial; two people on identical semaglutide doses may see weight loss differing by 50%.

Realistic Expectations by Starting BMI

BMI 27-30 (overweight): typical weight loss 15-25 lbs (7-12% body weight) by 24 weeks. BMI 30-35 (class I obese): typical weight loss 25-40 lbs (10-15% body weight) by 24 weeks. BMI 35-40 (class II obese): typical weight loss 40-60 lbs (12-18% body weight) by 24 weeks. BMI >40 (class III obese): typical weight loss 60-100+ lbs (15-22% body weight) by 24 weeks. These are averages; individual results vary by 50% in either direction. Achieving goal body weight requires combining semaglutide with other interventions; weight loss plateau typically occurs 15-25 lbs short of ideal weight for many individuals. Continued semaglutide use, increased exercise, or dietary intensification helps bridge this gap.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).